Arkolith/Insider Trading/YMAB/Form 4

LaRocca John

SVP, General Counsel & SecryY-mAbs Therapeutics, Inc. (YMAB) · full profile →Form 4 · filed Sep 18, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 16, 2025Disposed to issuer(D)22K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 16, 2025Disposed to issuer(D)143K——0
Sep 16, 2025Disposed to issuer(D)43K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001732197-25-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML